Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advances in Immunotherapy for Endometrial Cancer

Listen to Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of immunotherapy for the treatment of patients with endometrial cancer.

This podcast is intended for clinicians practicing medicine outside of the United States.

person default
Mansoor Raza Mirza, MD
Ana Oaknin, MD, PhD
Released: November 11, 2020

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of immunotherapy for the treatment of patients with endometrial cancer.

Presenters:

Ana Oaknin, MD, PhD
Head of Gynecologic Tumors Unit
Medical Oncology Department
Vall d´Hebron University Hospital
Barcelona, Spain 

Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology,
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark

Acknowledgements

Supported by an educational grant from
GlaxoSmithKline

Related Content

Comentario clínico en español sobre la reclasificación molecular de los cánceres de endometrio y ensayos clave de inmunoterapia en curso, de Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: May 10, 2021

Jubilee Brown, MD, and Ursula Matulonis, MD, discuss current challenges in the management of endometrial and ovarian cancer, from Clinical Care Options (CCO)

Jubilee Brown, MD Ursula Matulonis, MD Released: May 3, 2021

Download slides from Clinical Care Options (CCO) in which experts provide multidisciplinary insights on the use of checkpoint inhibitors for HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: April 30, 2021

From Clinical Care Options (CCO), webcast and downloadable slides on the use of PARP inhibitors to treat ovarian cancer, with Italian subtitles

person default Alexandra Leary, MD, PhD Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci person default Frederik Marmé, MD, PhD Released: April 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue